Evolent Health Q4 EPS Turns $0.08 vs $0.02 Loss, Shares Up 20.7%
Q4 non-GAAP earnings of $0.08 per share reversed a $0.02 loss a year ago on revenue of $468.7 million that matched expectations despite a 27.5% decline. Shares jumped 20.7% after Evolent forecast 2026 revenue of $2.4–$2.6 billion, implying 30% growth at the midpoint and about 5% above estimates.
1. Q4 Earnings Beat and Revenue
Evolent Health posted Q4 non-GAAP EPS of $0.08, reversing a prior year loss of $0.02, on revenue of $468.7 million that matched consensus despite a 27.5% year-over-year drop.
2. 2026 Guidance and Market Reaction
The company forecast full-year 2026 revenue of $2.4–$2.6 billion, implying roughly 30% growth at the midpoint and about 5% above analysts’ estimates, prompting a 20.7% share price surge even as adjusted EBITDA guidance fell short.
Related News
DE
Menon Bearings Posts 23% Revenue Gain, 51 New Parts for Deere Supply
DE•
PII
Polaris Launches $9,999 RANGER 500 and Installs 8,000 m² Solar Array
PII•
NVDA
Nvidia’s AI Chip Revenue Forecast Beats Estimates but Shares Drop 1.3%
NVDA•
MWC
Micware Co. Soars 51.5% in IPO Debut, Raises $22.8M
MWC•
NVO
Novo Nordisk Shares Slump 45% to 10x P/E as Pharma Fuels Danish GDP
NVO•
Sources
SF